Matrix metalloproteinases and clinico-morphological characteristic of ovarian neoplasms

N.E. Kushlinsky; E.S. Gershtein; N.V. Levkina; D.N. Kushlinsky; I.V. Tereshkina; K.P. Laktionov K.P.; L.V. Adamiyan

Matrix metalloproteinases and clinico-morphological characteristic of ovarian neoplasms

N.E. Kushlinsky¹, E.S. Gershtein², N.V. Levkina³, D.N. Kushlinsky⁴, I.V. Tereshkina⁵, K.P. Laktionov K.P.⁶, L.V. Adamiyan⁷

research article Pages: 52-57

¹ д.м.н., проф., член-корр. РАМН, зав. лабораторией клинической биохимии, Российский онкологический научный центр им. Н.Н.Блохина РАМН (Москва). E-mail: biochimiamtu-net.ru
² д.б.н., проф., лаборатория клинической биохимии, Российский онкологический научный центр им. Н.Н.Блохина РАМН
³ аспирант, отделение опухолей женской репродуктивной системы, Российский онкологический научный центр им. Н.Н.Блохина РАМН
⁴ аспирант, кафедра репродуктивной медицины и хирургии ФПДО, Московский медико-стоматологический университет
⁵ к.м.н., соискатель кафедры клинической биохимии и лабораторной диагностики ФПДО, Московский медико-стоматологический университет
⁶ д.м.н., проф., зав. отделением опухолей женской репродуктивной системы, Российский онкологический научный центр им. Н.Н.Блохина РАМН
⁷ д.м.н., проф., академик РАМН, зав. кафедрой репродуктивной медицины и хирургии ФПДО, Московский медико-стоматологический университет

Keywords: matrix metalloproteinase 2 matrix metalloproteinase 7 matrix metalloproteinase 9 matrix metalloproteinase tissue inhibitor type 1 ovarian neoplasms

Abstract

Matrix metalloproteinase (MMP) 7 and 9 levels were significantly increased and MMP-2 level was decreased in ovarian cancer tissue as compared to benign tumors.

MMP-7, MMP-9 and TIMP-1 concentrations in blood serum of ovarian cancer patients was significantly higher, and MMP-2 level - significantly lower than in control group of healthy women.

In the patients examined after presurgical therapy а comparative normalization of all parame-ters studied both in the tumors, and in serum was observed.

Significant positive association between MMP-7, MMP-9 and TIMP-1 serum levels and tumor size determined by ultrasound examination, and a positive correlation between these markers and CA125 serum values were demonstrated in ovarian cancer patients.

How to cite

Кушлинский Н.Е., Герштейн Е.С., Левкина Н.В., Кушлинский Д.Н., Терешкина И.В., Лактионов К.П., Адамян Л.В. Матриксные металлопротеиназы и клинико-морфологическая характеристика новообразований яичников // Технологии живых систем. 2010. № 8. С. 52–57.

References

Ашрафян Л.А., Киселев В.И.Опухоли репродуктивных органов (этиология и патогенез). М.: Изд-во «Династия». 2007. 208 c.
Новикова Е.Г., Ронина Е.А., Корнеева И.А. // Злокачественные опухоли яичников. Онкология. Национальное руководство / под ред. В.И. Чиссова, М.И. Давыдова. М.: ГЕОТАР Медиа. 2008. C. 812-819.
Хохлова С.В.Новый взгляд на лечение рака яичников // Опухоли женской репродуктивной системы. 2010. № 1. C. 68 -71.
Bast R. Updates on early detection and risk stratification for ovarian cancer. 38th Meeting of the International Society of Oncology and BioMarkers (ISOBM) (Munchen, September 3-8, 2010) // Tumor Biology. 2010. V. 31. Suppl.1. P. 122-123.
Cai K.Q., Yang W.L., Capo-Chichi C.D.et al. Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis // Mol. Carcinog. 2007. V. 46. № 2. P. 130-143.
Chobanian N., Dietrich C.S. Ovarian cancer // Surg. Clin. North Am. 2008. V. 88. P.285-299.
Demeter A., Sziller I., Csapo Z. et al. Molecular prognostic markers in recurrent and in non-recurrent epithelial ovarian cancer // Anticancer Res. 2005. V. 25Б. № 4. P. 2885-2889.
Deryugina E.I., Quigley J.P.Matrix metalloproteinases and tumor metastasis // Cancer Metastasis Rev. 2006. V. 25Б. № 1. P. 9-34.
Duhoux F.P., Machiels J.-P.Antivascular Therapy for Epithelial Ovarian Cancer // J. Oncology. 2009. V. 2010. Р. 1-16.
Goodman M.T., Shvetsov Y.B. Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995-2004 // Cancer Epidemiol Biomarkers Prev. 2009. V. 18. №.1. Р. 132-139.
Huang L.W., Garrett A.P., Bell D.A. et al. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors // Gynecol Oncol. 2000. V. 77. № 3. P. 369-376.
Kamat A.A., Fletcher M., Gruman L.M. et al. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer // Clin. Cancer Res. 2006. V. 12. № 6. P. 1707-1714.
Kurman R.J., Visvanathan K., Roden R., Wu T.C., Shih Ie M. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis // Am. J. Obstet. Gynecol. 2008. V. 198. № 4. Р.351-356.
Liotta L.A., Tryggvason K., Garbisa S.et al.Metastatic potential correlates with enzymatic degradation of basement membrane collagen // Nature. 1980. V. 284. № 5751. P. 67-68.
Maatta M., Talvensaari-Mattila A., Turpeenniemi-Hujanen T., Santala M. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours // Anticancer Res. 2007. V. 27. № 4C. P. 2753-2758.
Malemud C.J.Matrix metalloproteinases (MMPs) in health and disease: an overview // Front Biosci. 2006. V. 11. P. 1696-1701.
Ozalp S., Tanir H.M., Yalcin O.T. et al. Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression in epithelial ovarian tumors // Eur. J. Gynaecol. Oncol. 2003. V. 24. № 5. P. 417-420.
Perigny M., Bairati I., Harvey I. et al. Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer // Am. J. Clin. Pathol. 2008. V. 129. № 2. P. 226-231.
Ramnath N., Creaven P.J. Matrix metalloproteinase inhibitors // Curr. Oncol. Rep. 2004. V. 6. № 2. P. 96-102.
Rauvala M., Puistola U., Turpeenniemi-Hujanen T. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor // Gynecol. Oncol. 2005.
V. 99. № 3. P. 656-663.
Rauvala M., Turpeenniemi-Hujanen T., Puistola U. The value of sequential serum measurements of gelatinases and tissue inhibitors during chemotherapy in ovarian cancer // Anticancer Res.2006. V. 26. № 6C. P. 4779-4784.
Sillanpaa S., Anttila M., Suhonen K. et al. Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer // Tumour Biol. 2007. V. 28. № 5. P. 280-289.
Sillanpaa S., Anttila M., Voutilainen K. et al. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer // Gynecol. Oncol. 2007. V. 104. № 2. P. 296-303.
Sillanpaa S.M., Anttila M.A., Voutilainen K.A. et al. Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to beta-catenin expression // Int. J. Cancer. 2006. V. 119. № 8. P. 1792-1799.
Zaman K., Driscoll R., Hahn D. et al. Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy // Int. J. Cancer. 2006. V. 118. № 3. P. 755-764.

[1] Ашрафян Л.А., Киселев В.И.Опухоли репродуктивных органов (этиология и патогенез). М.: Изд-во «Династия». 2007. 208 c.

[2] Новикова Е.Г., Ронина Е.А., Корнеева И.А. // Злокачественные опухоли яичников. Онкология. Национальное руководство / под ред. В.И. Чиссова, М.И. Давыдова. М.: ГЕОТАР Медиа. 2008. C. 812-819.

[3] Хохлова С.В.Новый взгляд на лечение рака яичников // Опухоли женской репродуктивной системы. 2010. № 1. C. 68 -71.

[4] Bast R. Updates on early detection and risk stratification for ovarian cancer. 38th Meeting of the International Society of Oncology and BioMarkers (ISOBM) (Munchen, September 3-8, 2010) // Tumor Biology. 2010. V. 31. Suppl.1. P. 122-123.

[5] Cai K.Q., Yang W.L., Capo-Chichi C.D.et al. Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis // Mol. Carcinog. 2007. V. 46. № 2. P. 130-143.

[6] Chobanian N., Dietrich C.S. Ovarian cancer // Surg. Clin. North Am. 2008. V. 88. P.285-299.

[7] Demeter A., Sziller I., Csapo Z. et al. Molecular prognostic markers in recurrent and in non-recurrent epithelial ovarian cancer // Anticancer Res. 2005. V. 25Б. № 4. P. 2885-2889.

[8] Deryugina E.I., Quigley J.P.Matrix metalloproteinases and tumor metastasis // Cancer Metastasis Rev. 2006. V. 25Б. № 1. P. 9-34.

[9] Duhoux F.P., Machiels J.-P.Antivascular Therapy for Epithelial Ovarian Cancer // J. Oncology. 2009. V. 2010. Р. 1-16.

[10] Goodman M.T., Shvetsov Y.B. Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995-2004 // Cancer Epidemiol Biomarkers Prev. 2009. V. 18. №.1. Р. 132-139.

[11] Huang L.W., Garrett A.P., Bell D.A. et al. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors // Gynecol Oncol. 2000. V. 77. № 3. P. 369-376.

[12] Kamat A.A., Fletcher M., Gruman L.M. et al. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer // Clin. Cancer Res. 2006. V. 12. № 6. P. 1707-1714.

[13] Kurman R.J., Visvanathan K., Roden R., Wu T.C., Shih Ie M. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis // Am. J. Obstet. Gynecol. 2008. V. 198. № 4. Р.351-356.

[14] Liotta L.A., Tryggvason K., Garbisa S.et al.Metastatic potential correlates with enzymatic degradation of basement membrane collagen // Nature. 1980. V. 284. № 5751. P. 67-68.

[15] Maatta M., Talvensaari-Mattila A., Turpeenniemi-Hujanen T., Santala M. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours // Anticancer Res. 2007. V. 27. № 4C. P. 2753-2758.

[16] Malemud C.J.Matrix metalloproteinases (MMPs) in health and disease: an overview // Front Biosci. 2006. V. 11. P. 1696-1701.

[17] Ozalp S., Tanir H.M., Yalcin O.T. et al. Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression in epithelial ovarian tumors // Eur. J. Gynaecol. Oncol. 2003. V. 24. № 5. P. 417-420.

[18] Perigny M., Bairati I., Harvey I. et al. Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer // Am. J. Clin. Pathol. 2008. V. 129. № 2. P. 226-231.

[19] Ramnath N., Creaven P.J. Matrix metalloproteinase inhibitors // Curr. Oncol. Rep. 2004. V. 6. № 2. P. 96-102.

[20] Rauvala M., Puistola U., Turpeenniemi-Hujanen T. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor // Gynecol. Oncol. 2005.
V. 99. № 3. P. 656-663.

[21] Rauvala M., Turpeenniemi-Hujanen T., Puistola U. The value of sequential serum measurements of gelatinases and tissue inhibitors during chemotherapy in ovarian cancer // Anticancer Res.2006. V. 26. № 6C. P. 4779-4784.

[22] Sillanpaa S., Anttila M., Suhonen K. et al. Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer // Tumour Biol. 2007. V. 28. № 5. P. 280-289.

[23] Sillanpaa S., Anttila M., Voutilainen K. et al. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer // Gynecol. Oncol. 2007. V. 104. № 2. P. 296-303.

[24] Sillanpaa S.M., Anttila M.A., Voutilainen K.A. et al. Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to beta-catenin expression // Int. J. Cancer. 2006. V. 119. № 8. P. 1792-1799.

[25] Zaman K., Driscoll R., Hahn D. et al. Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy // Int. J. Cancer. 2006. V. 118. № 3. P. 755-764.

Abstract

How to cite

Related articles